Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
2021

Pushing the needle of entrepreneurship and innovation: Where do
plastic and reconstructive surgeons stand?
Sumun Khetpal
Yale University

Alvaro Reátegui
Yale University

Joseph Lopez
Yale University

Justin M. Sacks
Washington University School of Medicine in St. Louis

Adnan Prsic
Yale University

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
Khetpal, Sumun; Reátegui, Alvaro; Lopez, Joseph; Sacks, Justin M.; and Prsic, Adnan, ,"Pushing the needle
of entrepreneurship and innovation: Where do plastic and reconstructive surgeons stand?." Plastic and
Reconstructive Surgery - Global Open. 9,4. . (2021).
https://digitalcommons.wustl.edu/open_access_pubs/10367

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been
accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker.
For more information, please contact vanam@wustl.edu.

Special Topic
Pushing the Needle of Entrepreneurship and
Innovation: Where Do Plastic and Reconstructive
Surgeons Stand?

Downloaded from http://journals.lww.com/prsgo by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWnYQp/IlQrHD3i3D0OdRyi7TvSFl4Cf3VC1y0abggQZXdgGj2MwlZLeI= on 06/07/2021

Sumun Khetpal, BS, BA*
Alvaro Reátegui, BA*
Joseph Lopez, MD, MBA*
Justin M. Sacks, MD, MBA†
Adnan Prsic, MD*

Background: Plastic and reconstructive surgery has a well-recognized history of
disruption and innovation. It remains unclear, however, how the specialty’s priority on innovation materializes into commercialization or bench to bedside led by
plastic surgeons.
Methods: Our analysis utilized Pitchbook (Seattle, Wash.), a market database of
companies and investors, for ventures that have designed innovations related to
plastic and reconstructive surgery. Companies were categorized into 5 focus areas:
provider (outpatient surgical or hospital entity), aesthetics (cosmetics/injectables), devices (instrumentation, lasers, implants), regenerative medicine (tissue
engineering/wound healing), and software (digital solutions). Company websites,
LinkedIn (Sunnyvale, Calif.) profiles, and Crunchbase (San Francisco, Calif.) were
reviewed to determine the leadership roles of plastic surgeons.
Results: Plastic surgeons primarily serve as advisors, as opposed to founders or
chief executive officers (CEOs). Our analysis additionally found that provider and
software solutions had a greater degree of plastic surgeon-led leadership, whereas
regenerative medicine and device innovation remains less frequented. There was
a relatively balanced representation of academic and private plastic surgeons in
entrepreneurial pursuits.
Conclusions: Plastic surgeons typically serve as board advisors, as opposed to founders and CEOs. Reasons for disengagement from leadership roles may include satisfaction with clinical work, time constraint, lack of business knowledge, financial
constraint, and opportunity cost associated with starting a venture. To promote
participation in innovation, future studies should explore tangible ways to engage
in such opportunities. In doing so, plastic surgeons can own the “organ” of innovation, and continue to contribute to the legacy and the advancement of the specialty.
(Plast Reconstr Surg Glob Open 2021;9:e3557; doi: 10.1097/GOX.0000000000003557;
Published online 28 April 2021.)

INTRODUCTION

Plastic and reconstructive surgery has a well-recognized
history of disruption and innovation.1–6 Our specialty has
been defined by those who push the needle, such as Harry
Buncke, an innovator in microsurgery, Joseph Murray, the
Nobel Prize-winning pioneer of kidney transplantation,
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and Paul Tessier, a visionary for modern craniofacial surgery.7–9 These narratives have permeated to successive generations of plastic surgeons, and echo the foundational
principles of creativity and vision within our specialty.
Plastic surgeons do not “own” a single organ in the body,
and as a result, have relied on their ability to innovate to
confer a sense of identity within our broader surgical community.7 We have followed suit of our visionaries and have
ventured into new frontiers of our field—such as genderaffirming surgery, targeted muscle reinnervation, facial
transplantation, and the like—to contribute to the spirit
of innovation. This entails the translation of a new idea,
process, or product designed to save energy and improve
patient care. The inherent problem-solving nature of plastic surgery promotes a mindset of curiosity and inquiry.
Disclosure: Justin M. Sacks is the Co-Founder of LifeSprout
and Consultant of 3M. All the other authors have no financial interest in relation to the content of this manuscript. No
funding was received for this work.
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Plastic surgeons may source inspiration from the clinic,
operating room, research laboratory, from patients, colleagues, or the world outside the hospital. These discoveries often take shape in the form of research publications
and conference presentations for the academic community. However, others may channel this spirit of innovation
of their basic and clinical research through translation
through commercialization.
With the tremendous growth of the aesthetic surgery,
tissue engineering, and regenerative medicine industries,
plastic surgeons have unparalleled scientific and surgical
expertise with the potential to revolutionize our field.10,11
While some may file patents and pursue incorporation
as an organizational entity, others may choose to participate through key opinion leader (KOL) or advisory board
member roles. Regardless, it remains unclear how plastic
surgery’s priority of innovation materializes into opportunities for commercialization and how plastic surgeons
participate in such endeavors.
We hypothesize that plastic surgeons are well-represented in leadership roles within regenerative medicine
and device solutions, as their operative and clinical expertise offer valuable contributions within these sectors. We
additionally posit that there will be a greater proportion of
academic practice plastic surgeons, relative to their private
practice counterparts who engage in entrepreneurial pursuits, given their access to university-based resources such
as research laboratories, affiliated incubators, and adjunct
business schools. This investigation sought to understand
the role of plastic surgeons in ventures that pertain to the
specialty of plastic surgery.

METHODS

A retrospective review of United States-based plastic surgery companies was performed using Pitchbook
(Seattle, Wash.), a public market database composed of
companies and investors. Data were analyzed from investments posted in January 1, 2011 through December 31,
2019.12 Each company’s focus area was determined based
through Google search (Google LLC, Mountainview,
Calif.). Five focus areas were identified: provider (outpatient surgical or hospital entity), aesthetics (cosmetics/
injectables), devices (instrumentation, lasers, prosthetics,
implants), regenerative medicine (tissue engineering or
wound healing solutions), and software (digital solutions
for patients or surgeons). In addition, company websites,
LinkedIn (Sunnyvale, Calif.) profiles, Crunchbase (San
Francisco, Calif.), and Pitchbook were reviewed to determine the educational background and expertise of the
executive leadership team.12–14 Company websites that
were not in English were omitted for this analysis. The specific roles (ie, founder(s), chief executive officer (CEO),
chief medical officer (CMO), advisors, etc.) held by plastic
surgeons and other medical providers were recorded for
each company.

RESULTS

A total of 64 companies were included in the analysis.
Nearly a fifth (19%) of companies had plastic surgeons

2

as founders, and 9 (14%) had them as CEOs. Plastic surgeons more commonly served as board advisory members,
as they were represented in 23% of companies. Of the 40
plastic surgeons involved in various leadership positions,
there were 9 (23%) CEOs, 12 (30%) founders, 15 (37.5%)
advisors, and 4 (10%) CMOs (Fig. 1). There was a relatively even divide between the representation from academic (36%) and private practice (39%) surgeons. Of the
93 founders represented, 39 (42%) had MD or MD/PhD
degrees, followed by 22 (24%) having exclusively PhD
degrees, 16 (17%) with master’s (ie, MBA, MSE, MSc, etc),
13 (14%) with bachelor’s, 2 (2%) with JD, and 1 (1%) with
a high school diploma as the highest educational degree
completed (Fig. 2A). Approximately one-fifth of physicians were not plastic surgeons, and instead hailed from
dermatology, orthopedic surgery, and general medicine.
Of the 63 CEOs analyzed, 16 (25%) had MD, MD/PhD,
or MD/MBA degrees, 16 (25%) had PhDs, 17 (27%) had
some type of master’s degree, and 14 (22%) had a bachelor’s in this executive role (Fig. 2B).
In terms of focus area, there were 9 aesthetic companies, 13 device, 15 provider, 5 software, and 22 regenerative medicine solutions, amounting to a total of 64 ventures
analyzed. Plastic surgeons comprised a relatively larger
proportion of founders in software (60%) and provider
(33%) solutions, as opposed to regenerative medicine
(11%) and device (15%) solutions (Fig. 3A). In contrast,
plastic surgeons had a balanced representation across
focus areas, with the exception of regenerative medicine
and device solutions in CEO roles (Fig. 3B).

DISCUSSION

Our results reveal the under-representation of plastic
surgeons in the leadership structures of start-up ventures
related to their idea or specialty. This finding has many
potential origins. All are related potentially to the opportunity cost of choosing to run a start-up and of incurring
significant risk associated with foregoing reimbursement
associated with one’s own academic or private practice
and activities that might provide a greater chance of institutional advancement or promotion. Time constraint is an
additional consideration, as plastic surgeons must balance
responsibilities as full-time clinicians, principal investigators, and educators. Financial constraints could also serve
as a barrier to starting a company, as student debt and
personal obligations may preclude some from entrepreneurial endeavors. Moreover, instead of starting a company, plastic surgeons may elect to maintain relationships
with industry companies through serving as consultants,
organizing clinical studies, and receiving royalties for the
use of various devices, biologics, and software.15–18 On the
other hand, plastic surgeons may choose not to participate in the process of commercialization due to potential
conflicts of interest and concerns of how they are viewed
by the public, patients, and fellow colleagues.19–23 Finally,
entrepreneurship in the form of start-ups may be perceived as high risk and may require a certain level of
industry contacts and relationships with investors that
most plastic surgeons do not seek.
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Fig. 1. Roles of plastic surgeons in plastic surgery companies.

Fig. 2. A, Educational levels of founders for plastic surgery–related companies. B, Educational levels of CEOs for plastic surgery–related
companies.

If involved, we found plastic surgeons commonly
occupy roles on the advisory board. Such positions can
allow plastic surgeons to contribute their experiences
within academia, draw inspiration from their work, and
remain at the forefront of innovation amidst these constraints.24–26 This method of participation within commercialization and healthcare ventures has been increasingly
common among physicians in all specialties, in addition to
plastic surgery.24–26
According to our findings, plastic surgeons are more
likely to be founders or CEOs of companies that offer
provider solutions, such as private practices and ambulatory surgical centers (ASCs). Plastic surgeons may prefer
to pursue entrepreneurial opportunities that are closely
interlinked with daily surgical practice, as their reputational and financial success are dependent on favorable

surgical patient outcomes and clinical productivity. The
predominance of plastic surgeons as leaders in provider
solutions could also be attributed to the fact that the
majority of residency graduates pursue careers in private
practice. In fact, some studies have estimated that 67%–
90% of plastic surgeons choose this path, and thus often
serve in executive leadership positions (ie founder, CEO)
in such practices.27,28 Additionally, one could consider the
burgeoning role of ASCs, which have been regarded as
optimal sites for surgical intervention, cost reduction,
patient satisfaction, privacy, productivity, and convenience
to both plastic surgeons and patients.29 The Center for
Medicare and Medicare Services has also incentivized the
use of ASCs, providing greater reimbursement to surgeons
who are operative in these settings, as opposed to hospital outpatient departments.30 In all, provider solutions are
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Fig. 3. A, Percentage breakdown of plastic surgeons as founders by company focus. B, Percentage breakdown of plastic surgeons as CEOs
by company focus.

an accessible method by which plastic surgeons excel as
leaders, and concurrently provide a high quality of care
to their patients.
Software solutions, which comprise remote monitoring, virtual surgical planning, and telemedicine, were
most commonly (60%) led by plastic surgeons in executive leadership roles. This could be attributed to a promise of greater financial returns associated with digital
health ventures.31 However, these companies represented
only 8% of those analyzed in our study, and may suggest a lag of digital health applications in plastic surgery.
Interestingly, however, investment value in software and
digital health has increased by 858% and the number of
investments by 412%, in the past decade.31 Institutional
efforts have been taken to increase investment in digital
health, specifically the Food and Drug Administration
(FDA)’s establishment of the Digital Health Center of
Excellence. This entity aims to empower stakeholders to
advance healthcare through response and high-quality
innovation.32 Within the field of plastic surgery, there are
great opportunities for digital health ventures. Virtual surgical planning and simulation technologies are attractive
from the standpoint of offering precision care for optimal
aesthetic results for patients. Telemedicine, defined as the
use of information technology and telecommunication to
provide healthcare, has great potential for use within plastic surgery—whether through triaging trauma patients,
monitoring postoperative wounds, or performing consultations for elective procedures.33 With the resurgence of
the Coronavirus pandemic, digital heath solutions within
all specialties, including plastic surgery, will continue to
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rise in the coming months.34 Given the promise of digital
health innovation, we urge plastic surgeons to leverage
their surgical expertise and consider the applications of
software solutions for the sake of improving clinical outcomes and aesthetic results for patients.
Regenerative medicine solutions, composed of tissue
engineering and wound healing companies, had a low
representation (11%) of plastic surgeons as founders and
CEOs. Instead, engineers and research scientists, with
PhDs, comprised the vast majority of leaders in such companies. Furthermore, the FDA and national government
has increasingly prioritized innovation within regenerative
medicine, allocating greater research and development
funds through the 21st Century Cures Act.35 From a financial perspective, the tissue engineering market is quite
robust, as the market amounted to $9.0 billion in 2019,
and is expected to rise at a compound annual growth rate
of 14.2% from 2020 to 2027.4 Although plastic surgeons
have variable interests in the applications of basic science
to their specialty, it is important to consider how academic
plastic surgeons interact regularly within the fields of tissue engineering, 3-dimensional printing, and biologics in
the laboratory and thus, have great potential in translating their research discoveries to venture opportunities.
Surgeons have unparalleled insight into the issues affecting their patients, and can serve as a foundation of new
ideas and insights, as well as revision of older constructs.
Device companies, which manufacture lasers, surgical instruments, implants, and prosthetics, also had a low
representation (15%) of plastic surgeons in executive
leadership roles. Through advisory roles, plastic surgeons
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may contribute their perspective as chief users of various
devices; they may provide feedback regarding product
features, settings, and utilization to company representatives. They carry comprehensive knowledge of a given
device’s capabilities and limitations in a particular patient
or medical condition. This clinical and practical expertise
is unparalleled, and should serve as inspiration for plastic
surgeons to start ventures that design and deliver devices,
and ultimately, enhance care for patients.
There was a slightly greater representation of academic
plastic surgeons, compared with those in private practice, within executive leadership positions. Such engagement of academic plastic surgeons could be attributed
to their increased access to surgical innovation incubators, interdisciplinary expertise, and technology transfer
offices.36,37 Some academic institutions, such as University
of Michigan (Surgical Innovation and Entrepreneurship
Development Program), Stanford University (BioDesign),
University of Utah, University of Minnesota (Innovation
Fellows Program), Mayo Clinic (Center for Innovation),
and Northwestern University (NUvention), have
embraced an innovation agenda, spearheading a variety of
entrepreneurship development programs and internship
opportunities for surgical trainees.38–48 These programs
may educate aspiring surgeon-entrepreneurs on topics
such as product design, patent filing, licensing, talent
recruitment, shareholder equity, and fundraising to drive
clinical and research-borne innovations forward. These
opportunities may integrate the expertise of adjunct business, law, engineering, and design schools to build a wellversed, diverse team. We advocate for a continued effort
by academic plastic surgery sections and departments to
share these offerings with trainees and faculty and ultimately, encourage the utilization of these resources.38–48
More broadly, we recommend that national plastic surgery societies, such as the American Society of Plastic
Surgeons and the Plastic Surgery Foundation, similarly
encourage this agenda through offering seed grants and
pitch opportunities to spur innovation amongst private
and academic plastic surgeons. In addition, such societies may develop co-membership opportunities with other
entities, such as business schools and other medical societies (ie, dermatology, otolaryngology) to foster synergy and
commercialization.
To further explain their relative under-representation of leadership roles, plastic surgeons may abstain
from engaging in entrepreneurial pursuits due to lack
of business-related knowledge. Moreover, a recent study
surveyed plastic surgery program directors and discovered
discrepancies between perceived importance of a business
education and the resources available for plastic surgery
residents to learn about such concepts.49 Another study
reported that nearly 90% of plastic surgeon respondents
stated that business principles are either “pretty important” or “very important” to being a doctor.50–52 Efforts
to incorporate a business curriculum for plastic surgery
residents have been undertaken at several institutions,
such as Johns Hopkins University, Washington University
School of Medicine, and our own, Yale University.53 These
curricula have been administered through lecture series

and case discussions, and have educated on topics such
as billing and coding, leadership, investing, and negotiation. Despite these advances, the adoption of a standardized national curriculum within integrated plastic surgery
residencies is yet to occur. We urge such institutions to
leverage adjunct business, engineering, and law schools
to share instruction on the process of commercialization,
which may discuss the concrete steps that translate an idea
to clinical reality. Future studies should assess whether
such a curriculum translates to a greater probability of
starting ventures within plastic surgery.
There are several limitations to this study that warrant
consideration. First, our analysis does not have a record
of all nonpublic funding investments, and thus does not
account for all companies for which plastic surgeons
may participate in. Such data are not available through
Pitchbook. Second, the subjective characterization of
investments may have introduced uncertainties, and thus,
mislabeling of plastic surgeon engagement in various sectors. Third, while company websites, LinkedIn profiles,
and Crunchbase portals were assessed for involvement by
plastic surgeons, these might not have comprehensively
recorded their roles. This ultimately underestimates the
engagement of plastic surgeons in executive leadership
positions and informal advisory roles. Future studies could
survey national plastic surgery societies to attain more
granular information regarding participation and interest in commercialization and entrepreneurship. Fourth,
our study did not delve into the respective roles of academic and private plastic surgeons in a given commercial
endeavor. Future investigations could elucidate how a particular clinical setting may be associated with innovation
and formalized leadership in a given therapeutic area.

CONCLUSIONS

Despite these limitations, it is important to recognize
the immense potential for plastic surgeons to engage in
the process of commercialization. As a specialty known by
its drive to innovate, we urge plastic surgeons to consider
the application of their clinical and research-borne discoveries to impact patients beyond their scope of practice.
Bench to bedside progression of ideas can be a driving
force for innovation within the field of Plastic Surgery.
Provider and software solutions had a greater degree of
plastic surgeon-led leadership, and may reflect the tendency to interlink one’s daily surgical practice with entrepreneurship. Despite their emphasis on scientific and
surgical experience, regenerative medicine- and devicebased ventures had less involvement by plastic surgeons in
leadership positions. To promote participation within surgical innovation, future studies should explore tangible
ways in which plastic surgery residents, fellows, and attendings can learn about business fundamentals, connect with
a multi-disciplinary team, and leverage resources, such as
patent attorneys, technology transfer offices, and grants,
to be successful in their entrepreneurial pursuits. In doing
so, plastic surgeons can comprehensively own the space of
innovation, and contribute to the legacy of entrepreneurship so passionately instilled in all of us—for the sake of
patients and the advancement of the specialty.
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